Lorista

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorista

Quick Facts

Feature Detail
Active Ingredient Losartan potassium
Drug Class Angiotensin II Receptor Blocker (ARB)
Primary Use Treatment of high blood pressure (hypertension)

Lorista is a brand name for the prescription medication losartan potassium. Losartan belongs to a class of drugs known as Angiotensin II Receptor Blockers (ARBs). These medications work by targeting the renin-angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance.

How Lorista Works

Losartan functions by selectively blocking the binding of a potent hormone called angiotensin II to specific receptors, primarily the AT1 receptor, found in various tissues, including blood vessels and the adrenal gland. By blocking this action, losartan causes the blood vessels to relax and widen (vasodilation), which directly helps to lower blood pressure. A lower blood pressure helps the heart pump more efficiently and increases the supply of blood and oxygen to the heart.

Approved Medical Uses

Lorista (losartan) is primarily indicated for:

  • Treating High Blood Pressure (Hypertension): It is used alone or in combination with other medications to lower blood pressure in adults and children 6 years and older.
  • Reducing Stroke Risk: It is prescribed to lower the risk of stroke in patients with hypertension and a heart condition called left ventricular hypertrophy (an enlargement of the heart muscle).
  • Protecting Kidneys in Diabetes: It is also used to treat kidney disease (diabetic nephropathy) in patients who have Type 2 diabetes and a history of hypertension.

Lorista does not cure high blood pressure but is used to control it, and treatment often requires long-term adherence as directed by a healthcare provider.

What side effects are possible with Lorista?

Possible Side Effects and Safety Information

The safety profile of Lorista (losartan potassium) is structured by regulatory documents, categorizing adverse reactions based on frequency and affected body system.


Adverse Reaction Scope

Classification Examples of Reactions (by System-Organ Class)
Common (1% to < 10% incidence) Dizziness, headache, fatigue, upper respiratory infection, nasal congestion, back pain, diarrhea. (Nervous, General, Respiratory, Musculoskeletal, Gastrointestinal systems)
Rare (< 0.1% incidence) Angioedema, Anaphylaxis, Hepatitis (Immune system, Skin, Hepatobiliary systems)

Serious Adverse Reactions: Official labeling highlights rare, but clinically significant events such as angioedema (swelling of the face, lips, throat, or tongue) and severe hypersensitivity reactions, which are recognized safety concerns for this drug class.


Regulatory Safety Constraints

Population-Specific Safety: The use of losartan is contraindicated in women during the second and third trimesters of pregnancy due to the risk of fetal injury or death. It is also contraindicated in severe hepatic impairment due to significantly increased drug exposure in those patients. Safety notes also address caution in patients with renal impairment and volume depletion.

Exposure-Related Patterns: Hypotension (low blood pressure) is noted to be more frequently observed at the start of treatment or after dose adjustments, particularly in patients who are volume-depleted.

Safety Restrictions: The label specifies a contraindication for concomitant use with aliskiren in patients who have diabetes mellitus or renal impairment, due to an increased risk of complications including hyperkalemia (elevated potassium levels).

Overdose and Emergency Response

The regulatory information for Lorista (Losartan potassium) overdose is defined by the acute effects of over-exaggerated pharmacological action on the cardiovascular system.

Documented Overdose Manifestations

Overdose presentations primarily involve signs of profound hemodynamic instability. The most common clinical manifestations are hypotension (extremely low blood pressure) and heart rate changes, which may include tachycardia (rapid heart rate) or bradycardia (slow heart rate). Less severe presentations may include dizziness or fainting.

When to Seek Immediate Medical Help

The official guidance mandates seeking immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if a person exhibits severe symptoms such as collapse, a seizure, trouble breathing, or if they cannot be awakened. These severe symptoms indicate life-threatening symptomatic hypotension or central nervous system compromise requiring urgent care.

Supportive Management and Antidote Status

Treatment for Losartan overdose is entirely symptomatic and supportive. There is no specific antidote known for Losartan or its active metabolite. Management focuses on correcting the severe physiological effects, specifically through measures to restore intravascular volume and treat profound hypotension. Regulatory data also specify a critical constraint for management: hemodialysis is not effective for drug removal due to high protein binding. Separately, neonates with a history of in utero exposure must be closely monitored for hypotension and other related physiological effects.

Therapeutic Uses of Lorista

What Lorista Treats: Main Uses and Benefits

Lorista is commonly used for the sustained management of high blood pressure (hypertension). This medication is used to help reduce the strain associated with long-term high blood pressure on vital organs. It is considered relevant for use in conditions associated with high blood pressure, where additional support for cardiovascular and renal functional stability is needed.

Sustained Management and Protection

The use of this medication supports the management of high blood pressure, which helps address symptom clusters related to systemic imbalance. This supportive approach contributes to maintaining functional stability and managing the long-term burden associated with cardiovascular conditions.

The medicine is considered relevant for patients with conditions marked by increased physiological stress, such as high blood pressure. This supportive role contributes to improved comfort during symptomatic periods.

Quick Fact: Management of Systemic Stress

The medication is relevant for easing symptoms that create noticeable physiological strain, which contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. Losartan MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lorista — Official Regulatory Information

The eligibility profile for Lorista (losartan) is strictly defined by government regulatory documents, outlining populations that are allowed, restricted, or prohibited from use.


Category Official Regulatory Statement
Populations Allowed Adults ge 18 years of age. Children and adolescents ge 6 years of age (for hypertension only).
Populations Contraindicated Patients with known hypersensitivity to losartan. Women in the second and third trimesters of pregnancy. Patients with diabetes mellitus taking concomitant aliskiren therapy.

Age-Related Eligibility Rules

Use is not recommended for children under 6 years of age as safety and effectiveness have not been established. While older adults may display greater sensitivity, no general dose adjustment is required for geriatric patients.

Condition-Specific Eligibility Restrictions

  • Pregnancy: Lorista is contraindicated in the 2nd and 3rd trimesters and must be discontinued immediately if pregnancy is detected.
  • Organ Function: Patients with severe hepatic impairment are typically restricted from use. Patients who are volume- or salt-depleted must have the condition corrected before administration or start with a lower dose.
  • Renal Function: The medicine is not recommended for pediatric patients with an estimated GFR < 30 mL/min/1.73 m^2.

What should I know about interactions with other medicines?

Lorista (losartan) interacts with several classes of medicinal products, primarily impacting fluid and electrolyte balance or affecting the body's natural blood pressure regulation system.

Key Interaction Categories

Interacting Product Category Associated Risk and Restriction
Agents Increasing Serum Potassium (e.g., potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium) Risk: Hyperkalemia (high potassium levels). Restriction: Concomitant use is generally not recommended and requires close monitoring if unavoidable.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 Inhibitors Risk: Impairment of renal function and attenuation of the blood pressure-lowering effect. Restriction: Renal function should be monitored regularly during combined use.
Dual Blockade of the Renin-Angiotensin System (RAS) (e.g., with ACE inhibitors or Aliskiren) Risk: Increased rates of hypotension, hyperkalemia, and kidney function changes. Restriction: Use with Aliskiren is contraindicated in patients with diabetes. Dual RAS blockade is generally to be avoided.
Lithium Risk: Increased serum lithium concentrations, leading to potential toxicity. Restriction: Serum lithium levels must be monitored carefully if co-administered.
CYP450 Enzyme Modulators (e.g., Fluconazole, Rifampin) Effect: Can alter blood levels of losartan or its active metabolite, potentially affecting effectiveness. Restriction: May require increased surveillance of blood pressure control.

These interactions necessitate caution and often require specific laboratory monitoring, such as checking serum potassium and renal function, as officially documented in product labeling.

Mechanism of Action

Targeting the Angiotensin II Type 1 (AT1) Receptor

Lorista functions as a competitive antagonist at the Angiotensin II type 1 (AT1) receptor. This molecular interaction specifically blocks the binding of Angiotensin II, which is the endogenous ligand, thereby preventing AT1 receptor-mediated signaling pathways from being activated. This antagonistic action prevents the usual Gq-protein coupling and subsequent cellular responses.

Modulation of Systemic Physiology

The blockade of the AT1 receptor mediates the interruption of Angiotensin II-induced downstream effects. These mechanistic consequences include the cessation of direct vasoconstriction and a reduction in aldosterone secretion. The resulting modulation of circulating Angiotensin II activity affects renal hemodynamics, altering the efferent arteriolar tone, which, in turn, influences intraglomerular pressure. This core pharmacodynamic mechanism modulates the fluid and vascular system.

Dosage and Administration Information

Official Administration Guidelines

Lorista (losartan potassium) is administered according to a standardized, long-term protocol. The general principle of its use is a once-daily oral schedule, with specific starting doses and adjustments determined by the medical indication and patient characteristics.

Feature Official Instruction / Rule
Route of Administration Oral via tablet or a pharmacist-prepared suspension.
Standard Adult Dosing Starting Dose: Typically 50 mg once daily for hypertension or diabetic nephropathy.
Maintenance Dose: May be increased to a maximum of 100 mg once daily based on response.
Timing in Relation to Meals May be taken with or without food.
Frequency Pattern Once daily administration is the standard dosing frequency.

Procedural Considerations and Adjustments

Population-Specific Dosing: A lower initial dose of 25 mg once daily is directed for adult patients with mild-to-moderate hepatic impairment or for those who are considered volume-depleted (e.g., receiving high-dose diuretic therapy).

Pediatric Use: For children aged 6 to 16 years with hypertension, the starting dose is 0.7 mg/kg once daily, up to a 50 mg maximum initial dose. Use is not recommended for children under 6 years or those with severely reduced kidney function. Tablets should be swallowed whole with water.

Missed Dose: If a dose is missed, the standard procedure is to skip the missed dose and resume the regular schedule with the next planned dose, without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research has evaluated whether the drug affects the long-term prognosis for patients with heart failure. Research indicated that a lower rate of hospitalization for heart failure was reported in some study populations.

The clinical studies evaluated the combination drug against standard therapy.


Clinical Trials and Efficacy Data

Studies evaluated whether the combination of the Angiotensin Receptor Blocker (ARB) and the Neprilysin Inhibitor (NI) was compared with traditional treatments to assess specific endpoints.

Endpoint Assessment

The primary research focus examined whether the treatment influenced the combined rate of cardiovascular death and first hospitalization for heart failure.

  • Cardiovascular Mortality: Research findings indicated a lower incidence of cardiovascular death among trial participants.
  • Heart Failure Hospitalizations: A lower rate of hospitalization for worsening heart failure was reported in the treatment group in key trials.
  • Symptom Management: Research has explored the treatment's effect on symptoms of chronic heart failure and health status metrics.

Left Ventricular Function

The combination was studied regarding its effects on key metrics like left ventricular ejection fraction (LVEF), which is an indicator of the heart's pumping efficiency. This approach was examined in studies involving participants with reduced LVEF.


Safety and Tolerability Profile

The safety profile was assessed in adult participants. The frequency and severity of adverse events were documented in the trial reports.

  • Observed Side Effects: Certain side effects were observed in study participants. The frequency and severity of these events were documented in the trial reports.

Key Studies & References The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Lorista (FAQ)

Q: How long does it typically take for Lorista to start lowering blood pressure?

Official documents indicate that the active component of Lorista reaches its peak concentration in the blood within 3 to 4 hours of ingestion. The full, stable blood pressure lowering effect generally requires several weeks of consistent use to be established.


Q: Does Lorista lower blood pressure immediately?

The active component of the drug begins to work in the body shortly after it is taken. However, according to official data, the full, stable effect required to manage blood pressure is not immediate and typically takes several weeks of continuous and consistent use to be achieved.


Q: Can Lorista cause a persistent cough?

In clinical trials summarized in official documents, cough was reported as a possible adverse event. However, the reported frequency of cough was observed to be similar between those taking the drug and those taking a placebo.


Q: What is the difference between Lorista and Lisinopril?

Lorista (losartan) is officially classified as an Angiotensin II Receptor Blocker (ARB). This class works by directly blocking a specific receptor in the body. Lisinopril belongs to a different class called Angiotensin-Converting Enzyme (ACE) Inhibitors, which primarily work by reducing the production of Angiotensin II.


Q: Can women take Lorista while breastfeeding?

Regulatory information indicates that it is currently not known how much of the active ingredient passes into human breast milk. Due to this uncertainty, official guidance recommends seeking discussion with a healthcare provider regarding the use of this medication or the recommendation of an alternative.


Q: Does Lorista cause weight gain or weight loss?

Weight changes are not listed as common side effects in the official safety profile. It is noted, however, that the drug may rarely be associated with fluid retention, medically known as edema, which could result in unintended weight gain.


Q: Is it safe to drive or operate machinery after taking Lorista?

Official warnings state that caution should be exercised when driving or operating machinery. This is due to the potential for side effects such as dizziness or fainting, particularly when treatment is first started or the dosage is adjusted.


Q: Can Lorista affect my sleep?

Reports of sleep disorders are noted in official adverse event data as a less common side effect. If persistent issues with sleep are observed while on this medication, regulatory guidance suggests reporting them to a healthcare provider.


Q: Does Lorista need to be taken at a specific time of day?

Official administration guidelines state that Lorista is typically taken once daily. While the dose may be taken in the morning or evening, consistency is noted as important, and taking the medication at the same time each day is generally recommended in the labeling.


Q: Is Lorista a diuretic (water pill)?

No, Lorista (losartan) is classified as an Angiotensin II Receptor Blockant (ARB). Although it modulates fluid and blood pressure, it is not a diuretic itself. It may sometimes be prescribed together with a diuretic medication.


Q: What happens if I stop taking Lorista suddenly?

Official clinical trial summaries indicate that withdrawal effects, such as a sudden rebound in blood pressure, were not observed when the medication was stopped as part of the study protocol.


Q: Can Lorista interact with over-the-counter cold medicines?

Cold medicines often contain active ingredients, such as decongestants, that can potentially increase blood pressure or alter fluid balance. Official drug interaction guidance recommends consultation with a healthcare professional regarding their combined use.


Q: Does alcohol change how Lorista works in the body?

Official warnings indicate that alcohol may create an additive effect in lowering blood pressure. This increase in blood pressure reduction may elevate the risk of experiencing dizziness or fainting. The use of alcohol while on this medication is typically a matter for discussion with a healthcare provider.


Q: Is it common to have muscle cramps while taking Lorista?

Regulatory adverse reaction tables indicate that muscle cramps were reported in clinical studies as a possible side effect.


Q: Can Lorista make my skin more sensitive to the sun?

While photosensitivity (increased skin sensitivity to the sun) is not listed as a common side effect of Lorista, some medications in the same class (ARBs) have been associated with this reaction. Sun protection measures are generally noted as advisable when taking medications in this class.


Q: What are the symptoms of taking too much Lorista?

Official information on overdose describes the most likely symptoms as severely low blood pressure (hypotension). This may lead to pronounced dizziness or fainting, and could also potentially be accompanied by an abnormally fast or slow heartbeat.


Q: Can Lorista cause changes in mood or anxiety?

Official adverse event reports have noted effects related to the nervous system, including behavioral changes. Regulatory guidance indicates that if changes in mood or anxiety are observed while using this medication, they should be reported to a healthcare provider.


Q: What is the half-life of Lorista?

Official pharmacokinetic data indicates that the active ingredient, losartan, has a terminal half-life of about two hours. However, the active metabolite, which provides most of the blood pressure-lowering effect, has a significantly longer half-life, ranging from approximately six to nine hours.


Q: Is Lorista known by other brand names?

Yes, the active ingredient in Lorista, which is losartan potassium, is marketed globally under several different brand names. Official prescribing information often lists alternative brand names such as Cozaar.

How should Lorista be stored and disposed of?

The storage and disposal of Lorista (losartan potassium) must adhere to government-approved labeling to maintain product stability and ensure public safety.

Storage Requirement Official Standard
Temperature Range Store at 20 C to 25 C (Controlled Room Temperature), with excursions permitted between 15 C and 30 C.
Protection Keep the medication in the original container and tightly closed to protect it from light and moisture; do not freeze.
Child Safety Keep out of the sight and reach of children and pets, as many containers are not child-resistant.

For disposal, the drug is not on the FDA's flush list. Unused or expired Lorista should be discarded using a community drug take-back program. If a take-back option is unavailable, the medication must be removed from the container, mixed with an undesirable substance like coffee grounds, sealed in a bag, and then thrown in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorista found in:

A-Z Index: